João Vitor Heres
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
João Vitor Heres has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Arieli Cruz de Sousa
Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
1 shared publication - Augusto Ferreira Weber
Laboratory of Cancer Immunobiochemistry, Department of Biochemistry, Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil, Brazil
1 shared publication - Camila Kehl Dias
Laboratory of Cancer Immunobiochemistry, Department of Biochemistry, Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil, Brazil
1 shared publication - Fabrício Figueiró
Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil
1 shared publication - Fátima Costa Rodrigues Guma
Universidade Federal do Rio Grande do Sul
1 shared publication - Juliete Nathali Scholl
Laboratory of Cancer Immunobiochemistry, Department of Biochemistry, Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre 90610-264, RS, Brazil
1 shared publication
Latest Publications
- Open Access
- 15 January 2026
- Published by MDPI AG in Preprints.org
Integrating Transcriptomics and 3D Spheroid Models Reveals Microenvironment-Dependent Purinergic Modulation in Hepatocellular Carcinoma
Background/Objectives: Dysregulation of purinergic signaling influences tumor progression and immune evasion in hepatocellular carcinoma (HCC). We aimed to characterize the transcriptional landscape of this system, identify prognostic markers, and investigate how the tumor microenvironment modulates pharmacological response to combined sorafenib and doxazosin in 3D spheroid models. Methods: We integrated RNA-seq data from the TCGA-LIHC to identify differentially expressed genes, pathway enrichment, gene co-expression networks, prognostic associations, and machine learning-based biomarker selection. Modulation of key targets was assessed in HepG2 and HepG2/LX-2 spheroids treated with sorafenib and doxazosin using qPCR and flow cytometry. Results: Transcriptomics revealed dysregulation and network fragmentation, where high expression of ADA, NT5E, and ADORA1 correlated with poor overall survival. In 3D models, co-treatment significantly downregulated NT5E and ADORA1 mRNA expression, while ADORA2A was specifically reduced in the co-culture setting. For ADA, effect size analysis revealed a large magnitude of inhibition in HepG2 spheroids. Although flow cytometry showed high CD73 protein expression remained stable across treatments in co-culture, the combination therapy successfully overcame stromal protection, significantly increasing apoptosis (active caspase-3) in both mono- and co-culture spheroids compared to vehicle and monotherapy. Conclusions: We identified a purinergic prognostic signature in HCC and demonstrated that the combination therapy of sorafenib and doxazosin targets the adenosine-generating axis and specific receptors. We show that the stromal microenvironment sustains CD73 protein expression even under transcriptional inhibition, highlighting the critical role of 3D co-culture models in deciphering therapeutic resistance mechanisms.
- 15 January 2026
- Published by MDPI AG in Preprints.org
Open AccessIntegrating Transcriptomics and 3D Spheroid Models Reveals Microenvironment-Dependent Purinergic Modulation in Hepatocellular Carcinoma
Background/Objectives: Dysregulation of purinergic signaling influences tumor progression and immune evasion in hepatocellular carcinoma (HCC). We aimed to characterize the transcriptional landscape of this system, identify prognostic markers, and investigate how the tumor microenvironment modulates pharmacological response to combined sorafenib and doxazosin in 3D spheroid models. Methods: We integrated RNA-seq data from the TCGA-LIHC to identify differentially expressed genes, pathway enrichment, gene co-expression networks, prognostic associations, and machine learning-based biomarker selection. Modulation of key targets was assessed in HepG2 and HepG2/LX-2 spheroids treated with sorafenib and doxazosin using qPCR and flow cytometry. Results: Transcriptomics revealed dysregulation and network fragmentation, where high expression of ADA, NT5E, and ADORA1 correlated with poor overall survival. In 3D models, co-treatment significantly downregulated NT5E and ADORA1 mRNA expression, while ADORA2A was specifically reduced in the co-culture setting. For ADA, effect size analysis revealed a large magnitude of inhibition in HepG2 spheroids. Although flow cytometry showed high CD73 protein expression remained stable across treatments in co-culture, the combination therapy successfully overcame stromal protection, significantly increasing apoptosis (active caspase-3) in both mono- and co-culture spheroids compared to vehicle and monotherapy. Conclusions: We identified a purinergic prognostic signature in HCC and demonstrated that the combination therapy of sorafenib and doxazosin targets the adenosine-generating axis and specific receptors. We show that the stromal microenvironment sustains CD73 protein expression even under transcriptional inhibition, highlighting the critical role of 3D co-culture models in deciphering therapeutic resistance mechanisms.